On June 14, 2024, XNW27011, a new-generation Antibody-Coupled Drug (ADC) developed by Evopoint, has been granted Fast Track Designation (FTTD) statu...
Evopoint independently developed a new small molecule selective URAT1 inhibitor, XNW3009.
In the upcoming Year of the Loong, prosperity is anticipated, as the Dragon spreads its wings. Evopoint Biosesciences Co., Ltd. (hereinafter referred ...
Follow us
